Table 4.

Univariate Analysis of OS

Variable		mOS (Months)	X2	P
Method of treatment	Anlotinib alone	7	1.500	0.472
	Combined with chemotherapy	11
	Combined with immunotherapy	10
Method of treatment	Anlotinib alone	7	1.235	0.266
	Combined with chemotherapy or immunotherapy	11
Gender	Male	8	0.145	0.703
	Female	9
Age (years)	<60	9	0.392	0.531
	≥60	8
Smoking status	Yes	8	0.778	0.378
	No	9
Pathological type	Squamous cell carcinoma	8	2.218	0.330
	Adenocarcinoma	8
	Unknown	10
EGFR status	Wild type	9	6.226	0.04
	Mutant	5
	Unknown	9
ECOG PS	≤1	10	1.026	0.311
	>1	7
Number of treatment lines	<3	11	0.226	0.634
	≥3	8
Number of treatment lines	≤2	11	0.302	0.860
	3	9
	>3	8
Clinical stage	III	13.5	2.594	0.107
	IV	7
Previous EGFR-TKI treatment	Yes	7	0.123	0.726
	No	9
Previous thoracic radiation therapy	Yes	16	6.854	0.009
	No	7
Previous antivascular drug therapy	Yes	8	1.701	0.192
	No	8
Brain metastases	Yes	6	6.631	0.01
	No	10
Liver metastases	Yes	6	2.614	0.106
	No	10
Bone metastases	Yes	7	1.365	0.243
	No	9
Adrenal metastases	Yes	5	1.464	0.226
	No	9
Pleural metastases	Yes	7	1.072	0.301
	No	9
Number of distant metastases	≤2	9	5.515	0.019
	>2	5